Under accelerated review status, the FDA approves Seattle Genetics (NASDAQ:SGEN) and collaboration partners Astellas Pharma’s (OTCPK:ALPMF) antibody-drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and platinum-containing chemo before (neoadjuvant) or after (adjuvant) surgery.
SGEN will host a conference call tomorrow, December 19, at 9:00 am ET to discuss the approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.